Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 
Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.

	 

                    [DatePublished] => 2013-10-10 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 703067
                    [Title] => Roche's drug receives broader EU label  for women with metastatic breast cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
                    [DatePublished] => 2011-07-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 696213
                    [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
                    [Summary] => 
Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
                    [DatePublished] => 2011-06-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 691717
                    [Title] => Roche announces new study data  on rheumatoid arthritis treatment
                    [Summary] => 
Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
                    [DatePublished] => 2011-06-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 689458
                    [Title] => Roche bares study results on lung cancer medicine
                    [Summary] => 
Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 682217
                    [Title] => Roche drug for treating systemic juvenile  idiopathic arthritis gets US FDA approval
                    [Summary] => 
The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
                    [DatePublished] => 2011-05-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 678152
                    [Title] => Roche bares positive results of breast cancer drug
                    [Summary] => 
BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
                    [DatePublished] => 2011-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 671055
                    [Title] => Roche announces positive results for severe skin cancer medicine
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
                    [DatePublished] => 2011-03-31 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 657719
                    [Title] => Treatment helps women with ovarian cancer live significantly longer
                    [Summary] => 
Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
                    [DatePublished] => 2011-02-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DR. HAL BARRON

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 
Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.

	 

                    [DatePublished] => 2013-10-10 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 703067
                    [Title] => Roche's drug receives broader EU label  for women with metastatic breast cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
                    [DatePublished] => 2011-07-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 696213
                    [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
                    [Summary] => 
Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
                    [DatePublished] => 2011-06-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 691717
                    [Title] => Roche announces new study data  on rheumatoid arthritis treatment
                    [Summary] => 
Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.
                    [DatePublished] => 2011-06-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 689458
                    [Title] => Roche bares study results on lung cancer medicine
                    [Summary] => 
Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 682217
                    [Title] => Roche drug for treating systemic juvenile  idiopathic arthritis gets US FDA approval
                    [Summary] => 
The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.
                    [DatePublished] => 2011-05-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 678152
                    [Title] => Roche bares positive results of breast cancer drug
                    [Summary] => 
BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
                    [DatePublished] => 2011-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 671055
                    [Title] => Roche announces positive results for severe skin cancer medicine
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
                    [DatePublished] => 2011-03-31 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 657719
                    [Title] => Treatment helps women with ovarian cancer live significantly longer
                    [Summary] => 
Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
                    [DatePublished] => 2011-02-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest